Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adagene's EPS (Basic) for the
six
months ended in Jun. 2026 was €-0.25.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.33.
Adagene's EPS without NRI for the
six
months ended in Jun. 2026 was €-0.23.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.31.
During the past 3 years, the average EPS without NRIGrowth Rate was 42.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 34.40% per year.
During the past 8 years, Adagene's highest 3-Year average EPS without NRI Growth Rate was 52.90% per year. The lowest was -43.60% per year. And the median was 22.40% per year.
Adagene (FRA:978) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Adagene Earnings per Share (Diluted) Related Terms
Adagene Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Adagene's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:978 vs NGEN, NMRA, RNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Adagene's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagene PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adagene's PE Ratio distribution charts can be found below:
* The bar in red indicates where Adagene's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Adagene's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €-0.33 mean?
Adagene (FRA:978) has a Earnings per Share (Diluted) of €-0.33 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Adagene and its competitors. According to the industry distribution chart, Adagene ranks #232 out of 1161 companies in the Biotechnology industry, placing it in the top 20%.
Is Adagene's Earnings per Share (Diluted) too high?
Adagene's current Earnings per Share (Diluted) is €-0.33. Based on the distribution chart, Adagene ranks #232 out of 1161 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Earnings per Share (Diluted) compare to NGEN and NMRA?
According to the Biotechnology industry distribution chart, Adagene ranks #232 out of 1161 companies for Earnings per Share (Diluted). This places Adagene in the top 20% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 16.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.10, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Adagene and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adagene's current Earnings per Share (Diluted) is €-0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Earnings per Share (Diluted) of €-0.33. The stock's GF Value™ is €12.62, compared to a current price of €3.06 — trading 75.8% below its estimated fair value. The current Earnings per Share (Diluted) is €-0.33. Adagene's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Adagene (FRA:978), the current Earnings per Share (Diluted) is €-0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adagene (FRA:978) Overvalued in 2026?
Based on GuruFocus' analysis, Adagene stock appears to be undervalued.
The current stock price of €3.06 is trading 75.8% below its estimated GF Value™ of €12.62.
Key valuation signals for FRA:978:
Earnings per Share (Diluted): €-0.33
GF Value™: €12.62 vs. price of €3.06 (75.8% below fair value)
No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score
Get the complete analysis for FRA:978
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:978 has been successfully added to your 
